FOSUN HEALTH Logo

Leukemia FAQ

catalogue

Leukemia FAQ

Leukemia FAQ

The questions on this page come after the medical ones have been answered — what treatment will cost, how long the patient will be away from home, which drugs can actually be given here, and what happens on return. They are answered separately on purpose, because planning around them is what makes an intensive regimen easier to complete and a long one easier to sustain.

What treatment costs

Treatment in China typically costs 30% to 50% of the equivalent in Europe or the United States. The total depends on which parts of the pathway you need:

  • Diagnosis and molecular testing — the marrow examination, flow cytometry, chromosome analysis and gene testing, which are comparatively inexpensive individually but are what the whole plan depends on.
  • Chemotherapy phases — priced by the phase rather than the dose, so the total accumulates over induction, consolidation and, in acute lymphoblastic leukemia, maintenance over several years.
  • Targeted drugs — an oral tyrosine kinase inhibitor taken continuously, or a targeted agent added to chemotherapy; across months or years these become a substantial part of the total.
  • Cell therapy and transplant — the largest single components, because they require weeks of inpatient care, protective isolation, intensive support and prolonged follow-up.
  • Supportive care — anti-infective prophylaxis, transfusions, growth factors and complication management, individually modest and collectively a real part of the bill during intensive treatment.

How long you will need to stay

The length of a stay is determined by the type of leukemia rather than by any general rule:

  • Diagnosis and molecular testing — usually one to two weeks, since the marrow results and the molecular panel need time to be reported.
  • Induction for acute myeloid leukemia — an inpatient stay of four to six weeks, because counts fall before they recover and supportive care is needed throughout.
  • Consolidation — shorter admissions of a few days to a couple of weeks, with intervals between them.
  • Acute lymphoblastic leukemia — an initial stay measured in weeks, followed by a programme delivered partly as an outpatient over two to three years.
  • Chronic myeloid leukemia — no admission for routine treatment; monitoring is by blood tests, and most patients are seen as outpatients.
  • Transplant — several weeks of inpatient care including the period of low counts, followed by outpatient monitoring before travel is considered.

Which medicines are available

Most medicines used in leukemia internationally are available here:

  • Standard chemotherapy drugs — cytarabine, anthracyclines, vincristine, asparaginase and the others that make up the regimens, at the same doses used internationally.
  • All-trans retinoic acid and arsenic trioxide — the two drugs used to treat acute promyelocytic leukemia, which must be available without delay.
  • Tyrosine kinase inhibitors — several generations of them, including those active against the mutation that makes earlier drugs ineffective.
  • Other targeted agents — FLT3 inhibitors, IDH inhibitors and the BCL2 inhibitor used with a hypomethylating agent.
  • Bispecific antibodies and antibody-drug conjugates — including agents directed at CD19 and at CD22.
  • Bruton tyrosine kinase inhibitors — used continuously in chronic lymphocytic leukemia.
  • CAR T-cell therapy — engineered cells directed at CD19, for relapsed or refractory B-cell acute lymphoblastic leukemia.

Sending records and receiving a written opinion

The most useful thing to send is the original documents rather than a summary:

  • The marrow aspirate and biopsy reports, in full, or better the slides themselves, which allow the diagnosis to be reviewed directly rather than repeated.
  • The flow cytometry panel — the markers reported, since these define the lineage and provide the marker used later to measure residual disease.
  • The chromosome and molecular results — the full report rather than the conclusion, because the risk group is assigned from the details.
  • The treatment history — which regimen, which phases, the dates, any dose reductions, and the response at each assessment.
  • Recent blood counts — with the film report, and previous counts for comparison where available.

Insurance and payment

Coverage varies more than for most conditions, because so much of the cost sits in drugs:

  • Check whether the policy covers treatment outside your country of residence before assuming it does, and whether prior authorisation is required.
  • Check the drug coverage specifically — targeted agents taken continuously are often treated differently from inpatient care, and cell therapy is frequently excluded or capped.
  • Check the transplant cover, including donor search, the admission itself and the months of follow-up, since these are often bundled or limited.
  • Ask whether direct billing is available for your insurer, since paying and reclaiming is a different financial exercise from direct settlement, and the sums involved in transplant are large.
  • Request the documentation the insurer requires at the outset — a treatment plan, a cost estimate and clinical justification are usually needed, and they take time to assemble.

After treatment, and back home

Cross-border treatment makes written handover more important than in most conditions:

  • A written summary of the treatment actually given — drug names, cumulative doses including any anthracycline, the phases completed, and the response at the end of each.
  • A follow-up schedule with defined intervals — when counts and marrow assessments are due, and how the intervals lengthen over time.
  • Prophylaxis that continues — anti-infective medication, and the vaccination schedule, since live vaccines are avoided for a period after treatment.
  • Awareness of what to report — a new fever, unusual bruising or bleeding, or infections becoming more frequent, which may indicate that counts have fallen.
  • Late effects to watch for — cardiac function after an anthracycline, endocrine and thyroid function after total body irradiation, and graft-versus-host disease after a transplant.
  • A named contact, for questions between visits and for arranging a video review of results taken elsewhere.

Eating and daily life during treatment

No diet treats leukemia. What nutrition can do is support you through treatment:

  • Food safety matters more than food choice. During and after intensive chemotherapy the immune system is suppressed, so avoiding unpasteurised dairy, raw or undercooked meat, eggs and seafood, and unwashed produce is a concrete protective measure.
  • Adequate protein and calories to maintain weight, since weight loss during treatment is common and affects how the next phase is tolerated.
  • Mouth care — mucositis is common with several regimens, and rinsing, gentle cleaning and treating pain early make it manageable rather than a reason to stop eating.
  • Managing nausea and taste changes, which should be treated with adjusted anti-sickness medication rather than endured.
  • Neutropenic precautions at home — avoiding crowded settings during the lowest point of the blood count, and reporting a fever immediately rather than monitoring it.
  • Supplements — discussed with the team first, because some interact with treatment and some are marketed without evidence of benefit.

Frequently Asked Questions

How much does leukemia treatment cost in China?

Treatment in China typically costs 30% to 50% of the equivalent in Europe or the United States. The total depends on the type: chemotherapy phases accumulate over induction and consolidation, targeted drugs taken continuously form a substantial part of the cost over months or years, and cell therapy or transplant is the largest single component because of the weeks of inpatient care and prolonged follow-up it requires. Supportive treatment adds to the total during intensive phases. A formal itemised estimate is prepared from your own records and your proposed plan.

How long will I need to stay in China?

It depends on the type. Diagnosis and molecular testing usually take one to two weeks. Induction for acute myeloid leukemia involves four to six weeks in hospital, followed by shorter admissions for consolidation. Acute lymphoblastic leukemia begins with a stay measured in weeks and then continues partly as an outpatient over two to three years. Chronic myeloid leukemia needs no admission for routine treatment, only blood tests as an outpatient. A transplant involves several weeks of inpatient care plus outpatient monitoring before travel.

Are the same leukemia drugs available as in my own country?

Most are. Standard chemotherapy drugs, all-trans retinoic acid and arsenic trioxide, several generations of tyrosine kinase inhibitors, FLT3 and IDH inhibitors, the BCL2 inhibitor, bispecific antibodies, antibody-drug conjugates, Bruton tyrosine kinase inhibitors and CAR T-cell therapy are all available in our network. Availability of a specific agent depends on the hospital and the indication, so it should be confirmed in writing as part of the plan. If an agent approved elsewhere is not yet available here, ask what the realistic alternative is — often a drug of the same class, and sometimes a change to the regimen.

What should I bring, and what should I take home?

Bring the marrow aspirate and biopsy reports or the slides themselves, the flow cytometry panel, the chromosome and molecular reports, the treatment record with dates and any dose reductions, and recent blood counts with the film report. Take home a written summary of the treatment actually given with cumulative doses, a follow-up schedule with defined intervals, the prophylaxis and vaccination plan, guidance on what to report, and a named contact. The written record matters especially here, because late effects relate to the cumulative doses given years earlier.

Can follow-up be done by video after I return home?

Yes, for reviewing results and for decisions that do not require examination, arranged through a named contact rather than a general enquiry line. Blood counts and marrow results from your local centre can be sent to us, which is how most patients with the chronic leukemias conduct their follow-up — a tablet taken at home, monitored by a blood test every few months. Anything requiring examination, a marrow procedure or infusion has to be done in person.

What if the leukemia does not respond or comes back?

There is usually a defined next step, and it depends on the type and on what has already been given. Disease that does not clear after induction in acute myeloid leukemia is treated with a different regimen, often including a targeted drug matched to the mutation found at diagnosis. Disease that returns is treated with salvage chemotherapy, with a transplant considered if a second remission can be achieved. In B-cell acute lymphoblastic leukemia, a bispecific antibody, an antibody-drug conjugate or CAR T-cell therapy can be used; in chronic myeloid leukemia, a lack of response usually means switching tyrosine kinase inhibitor.

Patient Stories

Stories from our leukemia programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Ask before you commit to a treatment plan

Send the marrow reports, the flow cytometry panel, the chromosome and molecular results, the treatment already given and the latest blood counts. Our international patient team will return a written assessment within 48 hours of the file being complete, with an itemised estimate on request.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*